TxCell
Develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$79m (Public information from Jul 2018)
Company register number 435361209
Valbonne Provence-Alpes-Côte d'Azur (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.0m | 1.0m | 1.0m | <1m | <1m | 20.0m | 28.6m |
| % growth | - | (67 %) | - | (90 %) | (60 %) | 49900 % | 43 % |
| EBITDA | - | (10.0m) | (10.0m) | (10.0m) | (10.0m) | 2.0m | 2.6m |
| % EBITDA margin | - | (1000 %) | (1000 %) | (10000 %) | (25000 %) | 10 % | 9 % |
| Profit | - | - | - | (18.9m) | (13.6m) | 3.8m | 5.3m |
| % profit margin | - | - | - | (18926 %) | (33885 %) | 19 % | 19 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€10.5m | Series A | ||
€13.3m | Series B | ||
€12.4m | Series C | ||
| N/A | €16.2m Valuation: €63.6m | IPO | |
| N/A | €11.0m | Early VC | |
€1.2m | Post IPO Debt | ||
* | €72.0m Valuation: €72.0m 72.0x EV/LTM Revenues -7.2x EV/LTM EBITDA | Acquisition | |
| Total Funding | $51.9m | ||
Related Content
Recent News about TxCell
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.